Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism.

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

An ancient RNA-guided system with potential to expand gene-editing capabilities has been identified. Researchers at MIT’s McGovern Institute and the Broad Institute of MIT and Harvard (both MA, USA) ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

The 2012 landmark Science paper demonstrating the use of CRISPR-Cas9 as a gene-editing tool catapulted gene-editing technologies to new levels. Yet, that breakthrough also highlighted precision and ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing ...

A landmark Huntington's trial slows disease progression by 75%, signalling how RNA- and CRISPR-based tools redefine treatment for rare genetic disorders. Significant advancements in gene silencing and ...

Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of "genetic surgery" is performed on DNA, for ...

However, traditional gene delivery methods, such as Agrobacterium-mediated transformation and gene guns, are often slow, inefficient, and can damage plant tissues. These highlight the need for more ...